First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (neo)adjuvant trastuzumab

被引：0

作者：

Vaglica, M. ^{[1
]}

Lambertini, M. ^{[2
]}

Ferreira, A. ^{[3
]}

Poggio, F. ^{[2
]}

Puglisi, F. ^{[4
]}

Sottotetti, F. ^{[5
]}

Montemurro, F. ^{[6
]}

Poletto, E. ^{[4
]}

Pozzi, E. ^{[5
]}

Risi, E. ^{[7
]}

Lai, A. ^{[8
]}

Zanardi, E. ^{[9
]}

Sini, V. ^{[10
]}

Ziliani, S. ^{[11
]}

Minuti, G. ^{[12
]}

Mura, S. ^{[13
]}

Grasso, D. ^{[14
]}

Ferrarini, I. ^{[15
]}

Pronzato, P. ^{[2
]}

Del Mastro, L. ^{[1
]}

机构：

[1] IRCCS AOU San Martino IST, Med Oncol, UO Sviluppo Terapie Innovat, Genoa, Italy

[2] IRCCS AOU San Martino IST, UO Oncol Med 2, Genoa, Italy

[3] Hosp Santa Maria, Inst Med Mol, Lisbon, Portugal

[4] Univ Hosp, Oncol, Udine, Italy

[5] Fdn Maugeri IRCCS, Med Oncol, Pavia, Italy

[6] Fdn Piemonte Oncol, Ist Candiolo IRCCS, Unit Invest Clin Oncol, Candiolo Torino, Italy

[7] Univ Roma La Sapienza, Radiol Oncol & Human Pathol, Oncol Unit B, I-00185 Rome, Italy

[8] Azienda Osped Univ, Med Oncol, Sassari, Italy

[9] IRCCS AOU San Martino IST, Med Oncol, Clin Oncol Med, Genoa, Italy

[10] Univ Roma La Sapienza, St Andrea Hosp, Oncol, I-00185 Rome, Italy

[11] Osped San Paolo, Med Oncol, Savona, Italy

[12] Civil Hosp, Ist Tumori Toscano, Med Oncol, Livorno, Italy

[13] Osped Santissima Annunziata, Oncol, Sassari, Italy

[14] IRCCS San Matteo Univ Hosp Fdn, Med Oncol, Pavia, Italy

[15] Azienda Osped Univ Pisana, Polo Oncol, Pisa, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30813-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1863

引用

页码：S286 / S286

页数：1

共 50 条

[1] First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (NEO) adjuvant trastuzumab
Vaglica, M.
Vaglica, M.
Lambertini, M.
Ferreira, A.
Poggio, F.
Puglisi, F.
Sottotetti, F.
Montemurro, F.
Poletto, E.
Pozzi, E.
Risi, E.
Lai, A.
Zanardi, E.
Sini, V.
Ziliani, S.
Minuti, G.
Mura, S.
Grasso, D.
Ferrarini, I.
Pronzato, P.
Del Mastro, L.
ANNALS OF ONCOLOGY, 2015, 26 : 6 - 7
[2] Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: A monoinstitutional experience
Spazzapan, S.
Crivellari, D.
Tumolo, S., V
Russo, A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[3] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
Del Mastro, Lucia
Lambertini, Matteo
Bighin, Claudia
Levaggi, Alessia
D'Alonzo, Alessia
Giraudi, Sara
Pronzato, Paolo
EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
[4] Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
Carlos Acevedo-Gadea
Christos Hatzis
Gina Chung
Neal Fishbach
Kimberly Lezon-Geyda
Daniel Zelterman
Michael P. DiGiovanna
Lyndsay Harris
Maysa M. Abu-Khalaf
Breast Cancer Research and Treatment, 2015, 150 : 157 - 167
[5] Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
Acevedo-Gadea, Carlos
Hatzis, Christos
Chung, Gina
Fishbach, Neal
Lezon-Geyda, Kimberly
Zelterman, Daniel
DiGiovanna, Michael P.
Harris, Lyndsay
Abu-Khalaf, Maysa M.
BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (01) : 157 - 167
[6] Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience
Carli, Paolo
Militello, Loredana
Miolo, Gian Maria
Quitadamo, Daniela
Lombardi, Davide
Torrisi, Elena
Scalone, Simona
Crivellari, Diana
Spazzapan, Simon
TUMORI, 2014, 100 (06) : 605 - 611
[7] Trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer
Biswas, Bivas
Rastogi, Sameer
Batra, Atul
Ganguly, Sandip
NATIONAL MEDICAL JOURNAL OF INDIA, 2016, 29 (04): : 219 - 220
[8] Trastuzumab therapy in HER2-positive, metastatic breast cancer
Smith, A. D.
Guilbert, K.
Lister, D.
Streilein, S.
Bourrier, V. C.
Lozar, B.
Navaratnam, S.
Harding, G. A.
Pitz, M. W.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[9] Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab
Bian, Li
Wang, Tao
Zhang, Shao-hua
Zhang, Hui-qiang
Guo, Yun-fei
Du, Ge
Li, Wang
Wu, Shi-kai
Song, San-tai
Jiang, Ze-fei
CANCER BIOLOGY & THERAPY, 2014, 15 (04) : 365 - 370
[10] Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2-positive breast cancer.
Lang, I.
Bell, R.
Feng, F.
Lopez, R. I.
Jassem, J.
Semiglazov, V.
Al-Sakaff, N.
Carreras, E.
Chang, J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →